Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | DUT | P33316 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18594653 | 0.79 | POLB (0.46) | HPGDHDAC2SMN1; SMN2POLBLMNA | |
| SCHEMBL5893326 | 0.79 | LMNA (0.56) | HPGDHDAC2SMN1; SMN2POLBLMNA | |
| SCHEMBL10989343 | 0.79 | HPGD (0.53) | HPGDHDAC2SMN1; SMN2POLBLMNA | |
| SCHEMBL18562053 | 0.78 | ALDH1A1 (0.34) | HPGDALDH1A1 | |
| SCHEMBL19176633 | 0.77 | HPGD (0.45) | HPGDHDAC2SMN1; SMN2POLBLMNA | |
| SCHEMBL13761839 | 0.77 | HPGD (0.51) | HPGDHDAC2SMN1; SMN2POLBLMNA | |
| SCHEMBL18177038 | 0.75 | HPGD (0.50) | HPGDHDAC2SMN1; SMN2POLBLMNA | |
| SCHEMBL20214935 | 0.75 | HPGD (0.50) | HPGDSMN1; SMN2POLBLMNAALDH1A1 | |
| SCHEMBL19171550 | 0.75 | SMN1; SMN2 (0.50) | HPGDHDAC2SMN1; SMN2POLBLMNA | |
| SCHEMBL22916866 | 0.73 | FAAH (0.45) | HPGDSMN1; SMN2POLBLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | CHINOOK THERAPEUTICS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-10787480-B2 | Cytotoxic peptides and conjugates thereof | NOVARTIS AG (CH) | 2020-09-29 | — | — | US | disclosed |
| US-9988420-B2 | Cytotoxic peptides and conjugates thereof | NOVARTIS AG (CH) | 2018-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787480-B2 | Cytotoxic peptides and conjugates thereof | CD47, NGLY1, VIP | HPGD 3718/4885HDAC2 4552/4885SMN1; SMN2 2012/4885 |
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | STING1, TLR9, TLR3 | HPGD 3849/4885HDAC2 3979/4885SMN1; SMN2 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.